RNA Formulation Resources

31. The Key To Accelerating RNA-LNP Drug Development 12/27/2023

    Learn about the drug development hurdles that must be overcome to deliver on the promise of mRNA.

32. Delivering The Promise Of Gene Therapy 1/22/2024

    Gene therapies rely on efficient, precise methods of delivering genetic material. Examine how combining polymeric nanoparticles with CRISPR therapies is increasing the potential for improved treatment.

33. Versatile Lipid Nanoparticle Platform For Efficient Gene Editing 6/3/2025

    Lipid nanoparticles enable efficient gene editing in hard-to-transfect cells like T-cells and blood stem cells, which offers scalable, clinically relevant methods for developing advanced therapies for cancer and rare diseases.

34. Continuous Nanoparticle Manufacturing For Gene Editing Delivery 9/18/2025

    Messenger RNA-LNPs are a promising strategy for delivering gene-editing components. Learn how a continuous manufacturing platform can address the scalability and reproducibility challenges of this process.

35. Developing A Scalable RNA-LNP Drug Product For Clinical Translation 9/22/2022

    Accelerate essential process development activities with instrumentation solution allowing for highly reproducible and scalable production of RNA-LNPs.

36. Development And Optimization Of LNP Formulations 12/6/2024

    The production of lipid nanoparticles (LNPs) is a process that demands robustness, scalability, and reproducibility. Examine the impact of key operational parameters on the efficacy of LNPs.

37. Advancing A LNP Formulation To Clinical And Commercial Manufacturing 3/25/2024

    Lipid selection impacts the final LNP drug product and the LNP process. Review critical quality considerations for lipids and the process requirements for successful commercial-scale manufacturing.

38. Replicate Bioscience And Cytiva Collaborate To Deliver srRNA-LNP Vaccines 3/24/2025

    Discover how self-replicating RNA (srRNA) can revolutionize vaccine development with sustained protein expression, lower doses, and fewer side effects to advance next-gen RNA therapeutics.

39. Turbulent Mixing: Scaling Up Nanoparticle Manufacturing For The Future

    Choosing between turbulent and microfluidic mixing methods in your lipid nanoparticle (LNP) production can have a significant impact when scaling up production.

40. Novel Lipid Nanoparticle Delivery Reagent And Manufacturing Workflow 4/18/2022

    We aim to highlight that commercially available LNP reagent mix, GenVoy-ILM, is an accessible and easy-to-use LNP formulation that allows for rapid preclinical development of RNA vaccines.